Overview

Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients

Status:
Recruiting

Trial end date:
2023-08-04

Target enrollment:
0

Participant gender:
All

Summary

Prospective phase IV interventional open label randomized controlled trial to assess safety and efficacy of glutamine in preventing vaso-occlusive crisis (VOC) episodes in sickle cell pediatrics and adolescents' patients

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ain Shams University

Criteria

Inclusion Criteria:

Children and adolescents diagnosed with sickle cell disease by haemoglobin electrophoresis
and had at least two pain crises (no upper limit) documented during the previous year; a
pain crisis is defined as pain leading to treatment with a parenteral administered narcotic
or ketolac in an emergency department (ED) (or outpatient treatment centre) or during
hospitalization.

Patients receiving hydroxyurea at a fixed dose for at least 3 months before screening.

Exclusion Criteria:

Patients with sickle cell trait and other hemoglobinopathy.

-